These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12235178)

  • 1. Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
    Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Barrett PH; Dubreuil D; Roy M; Bernier L; Mamer O; Davignon J
    J Lipid Res; 2002 Sep; 43(9):1464-71. PubMed ID: 12235178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
    Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
    J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
    Ooi EM; Ng TW; Watts GF; Chan DC; Barrett PH
    J Lipid Res; 2012 Nov; 53(11):2443-9. PubMed ID: 22930812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.
    Schwaiger JP; Nakada Y; Berberich R; Ikewaki K; Dieplinger B; Zitt E; Neyer U; Salmhofer H; Kronenberg F; Koenig P; Dieplinger H
    Clin J Am Soc Nephrol; 2013 Aug; 8(8):1319-26. PubMed ID: 23599405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Cohn JS; Wilson A; Wolfe ML; Nartsupha C; Schaefer PM; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    J Lipid Res; 2008 Mar; 49(3):543-9. PubMed ID: 18033754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
    Parhofer KG; Barrett PH; Schwandt P
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4224-30. PubMed ID: 11095458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.
    Brunzell JD; Albers JJ; Chait A; Grundy SM; Groszek E; McDonald GB
    J Lipid Res; 1983 Feb; 24(2):147-55. PubMed ID: 6403642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR; Barrett PH; Vicini P; Miller DB; Telford DE; Kleinstiver SJ; Huff MW
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1906-14. PubMed ID: 9848883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.